Published in J Cancer Res Clin Oncol on January 01, 1990
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A (1997) 2.36
An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med (1999) 2.10
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
Programmed cell death (apoptosis) in human monocytes infected by influenza A virus. Immunobiology (1994) 1.98
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A (1999) 1.74
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol (1996) 1.73
Endothelial-like cells derived from human CD14 positive monocytes. Differentiation (2000) 1.73
Isolation of elastase-like and chymotrypsin-like neutral proteases from human granulocytes. Hoppe Seylers Z Physiol Chem (1974) 1.62
Quantification of postural sway in normals and patients with cerebellar diseases. Electroencephalogr Clin Neurophysiol (1984) 1.57
Contiguous pattern spreading in patients with Hodgkin's disease. Radiother Oncol (1998) 1.55
Kinetics of pulmonary leukocyte sequestration in man during hemodialysis with different membrane-types. Int J Artif Organs (1990) 1.40
De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol (1996) 1.40
[Adjuvant therapy in colonic carcinoma]. Dtsch Med Wochenschr (1991) 1.39
The isolation and partial characterization of linked alpha A- and alpha D-globin genes from a duck DNA recombinant library. Gene (1982) 1.35
Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol (1995) 1.35
Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer (1980) 1.29
Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1997) 1.28
Early stabilization of human posture after a sudden disturbance: influence of rate and amplitude of displacement. Exp Brain Res (1984) 1.25
Bisamides, lignans, triterpenes, and insecticidal Cyclopenta[b]benzofurans from Aglaia species. J Nat Prod (1998) 1.22
Characteristic alterations of long-loop "reflexes" in patients with Friedreich's disease and late atrophy of the cerebellar anterior lobe. J Neurol Neurosurg Psychiatry (1984) 1.19
Studies in chronic lymphocytic leukemia: further studies of the proliferative abnormality of the blood lymphocyte. Blood (1969) 1.17
Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood (1977) 1.16
Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer (1991) 1.16
Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol (1987) 1.15
Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-alpha (TNF alpha) gene expression. Res Virol (1997) 1.15
Insecticidal flavaglines and other compounds from Fijian Aglaia species. Phytochemistry (2001) 1.15
Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation (1988) 1.15
Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res (1988) 1.14
The delayed response of c0ronic lymphocytic leukemia lymphocytes to phytohemagglutinin in vitro. Proc Soc Exp Biol Med (1968) 1.14
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13
Adherence to pharmacologic management of hypertension. Can J Public Health (1999) 1.12
Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol (1984) 1.12
Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol (2001) 1.10
Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer (1996) 1.10
Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol (1993) 1.06
Primary osteosarcoma of the breast--case report and review of the literature. Acta Oncol (1994) 1.06
Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol (1987) 1.05
Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro. J Clin Invest (1978) 1.03
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol (1989) 1.02
The complete nucleotide sequence of the duck alpha A-globin gene. Gene (1982) 1.02
Expression of bcl-2--protein in small cell lung cancer. Lung Cancer (1996) 1.02
[Phytohemagglutinin (PHA) and serum proteins in lymphocyte culture. I. Demonstration of promotor and inhibitory serum factors]. Z Gesamte Exp Med (1970) 1.01
Proteolytic cleavage of human IgG molecules by neutral proteases of polymorphonuclear leukocytes. Eur J Immunol (1978) 1.00
Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol (1987) 0.99
Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF). Br J Haematol (1992) 0.99
Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology (1997) 0.98
Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer (1997) 0.97
Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thromb Res (1975) 0.97
Carcinoembryonic antigen and ferritin in patients with lung cancer before and during therapy. Cancer (1978) 0.96
Characterization of a high molecular weight tumor necrosis factor-alpha mRNA in influenza A virus-infected macrophages. J Immunol (1994) 0.95
Medium and long latency EMG responses in leg muscles: Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 0.93
Sonographic patterns of the affected spleen in malignant lymphoma. J Clin Ultrasound (1990) 0.93
Androgen receptors, androgen-dependent proliferation, and 5 alpha-reductase activity of small-cell lung cancer cell lines. Int J Cancer (1989) 0.93
The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol (1989) 0.93
Long latency EMG responses in hand and leg muscles: cerebellar disorders. J Neurol Neurosurg Psychiatry (1987) 0.92
Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep (1983) 0.92
Disturbances of motor preparation in basal ganglia and cerebellar disorders. Prog Brain Res (1989) 0.92
Improvement of ataxia in alcoholic cerebellar atrophy through alcohol abstinence. J Neurol (1984) 0.91
Protease activity as a possible mechanism of migration inhibitory factor. Eur J Immunol (1972) 0.91
Macrophage migration inhibitory factor production by Leydig cells: evidence for a role in the regulation of testicular function. Endocrinology (1996) 0.91
Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol (1993) 0.91
Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol (1987) 0.90
NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett (1990) 0.90
TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med (1997) 0.90
The significance of delayed long-loop responses to ankle displacement for the diagnosis of multiple sclerosis. Electroencephalogr Clin Neurophysiol (1984) 0.90
Adherence to management of high blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Public Health (1999) 0.90
HLA matching in autoimmune thrombocytopenic purpura. Br J Haematol (1977) 0.89
Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer (1987) 0.88
Infraspecific variation of sulfur-containing bisamides from Aglaia leptantha. J Nat Prod (2000) 0.88
Stress induced carbazole phytoalexins in Glycosmis species. Phytochemistry (2001) 0.88
Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler (1991) 0.88
Production of immunoreactive insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines. Exp Cell Res (1988) 0.88
Envelope and long terminal repeat sequences of an infectious murine leukemia virus from a human SCLC cell line: implications for gene transfer. Virus Genes (1998) 0.88
Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res (1987) 0.88
Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation (1998) 0.87
Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis (1993) 0.87
Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene (1989) 0.86
Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol (2000) 0.86
External distraction of the maxilla in patients with craniofacial dysplasia. J Craniofac Surg (2001) 0.86
[Differential reaction of lymphocytes to phytohemagglutinin (PHA) in liver diseases]. Klin Wochenschr (1969) 0.86
Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester. Int J Cancer (1990) 0.86
Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol (1999) 0.86
Glucocorticoid receptors and growth inhibitory effects of dexamethasone in human lung cancer cell lines. Eur J Cancer (1995) 0.86
[The passive transmission of the Kveim reaction with blood lymphocytes]. Klin Wochenschr (1968) 0.85
Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol (1987) 0.85
Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects. J Cancer Res Clin Oncol (1988) 0.85
Characterization of two cell lines with distinct phenotypes established from a patient with small cell lung cancer. Cancer Res (1987) 0.85
Incidence of circulating immune complexes in patients with lung cancer and their effect on antibody-dependent cytotoxicity. Oncology (1980) 0.84
Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol (1997) 0.84
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res (1989) 0.84
[Chemotherapy and combined chemoradiotherapy procedures in bronchial carcinoma]. Internist (Berl) (1994) 0.84